• Increase font size
  • Default font size
  • Decrease font size

ADVENTRX: Upcoming News Event and Very Positive Technical Analysis

Print E-mail
By M.E.Garza   
Thursday, 17 December 2009 09:45

Subscribers were alerted to this stock this morning and it traded up nicely. The good news is, it's expected to go higher in the coming days given it's important forward looking news event and undervalued price.

This company just had a presentation at the Lippert/Heilshorn Life Sciences Conference (12/15/09) (look through the slides here) and we issued a breakout alert on it early this morning to our subscribers.

They have a great looking chart and some upcoming news events that will likely see it trading higher in the coming days- especially one that involves the submission of an NDA (new drug application) before the end of the year and two late stage programs that are promising high-return on investment.

ADVENTRX Pharmaceuticals, Inc.

(AMEX:ANX)

Cick to Open Chart

As always, do your own DD. This is an AMEX stock that trades before and after market hours.

 

Disclosure: long ANX





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 1 hour ago NHS education reforms 'lack detail' http://t.co/YiUKVEsS
about 1 hour ago Molecular 'on-off' switch for Parkinson's disease discovered http://t.co/wZ1N0xhq
about 1 hour ago Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent http://t.co/CnJ8fKok
about 1 hour ago Roche's dalcetrapib failure fuels HDL debate, but CETP not done yet http://t.co/8H9JRnp9
about 1 hour ago Modest Gains Vanish As Stocks Reverse Lower http://t.co/AXlpfiAP
about 1 hour ago Reading: One More Reason the Market's Pullback is Not Over http://t.co/iSZ0oYUq
about 8 hours ago Novo’s Insulin Pill Quest is Holy Grail for Novo: Health http://t.co/1NixK9Mx
about 8 hours ago Bayer's Nexavar fails in lung cancer but FDA staff keen on Xarelto for ACS http://t.co/9VZRVqqD

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified